1. Volume 23, Issue 9, Pages 1532-1540 (September 2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer 
Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, Jae-Hee Mun, Erica M Sommermann, Liliana Maruri Avidal, Rick Patt, Adina Pelusio, James Burke, Tae-Ho Hwang, David Kirn, Young Suk Park 
Molecular Therapy 
Volume 23, Issue 9, Pages (September 2015)
DOI: /mt
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Pexa-Vec-related skin pustules. Pexa-Vec related pustule onset and resolution of two pustules in patient JX (a) and one pustule in patient JX (b).
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Pexa-Vec pharmacokinetics following multiple IV infusions. (a) Quantitative polymerase chain reaction detection of Pexa-Vec genomes in blood after cycles 1–4. Mean genomes/ml were calculated after removing individual patient values that were below the limit of detection (LOD). The solid marker indicates that the mean value at a time point is based on three samples for Cohorts 1 and 2 and nine samples (D1 and D15), eight samples (D29), or seven samples (D43) for Cohort 3. The “x” marker indicates that there were only two samples above the LOD used to calculate the mean value. The unfilled marker indicates that the value of the time point is based on only one sample above the LOD. (b) Pexa-Vec pfu detection in plasma after cycle 1. (c) Pexa-Vec pfu detection in plasma after cycle 4.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

4. Figure 3
Cytokine detection in plasma. Cytokine concentrations were measured in plasma before and after each cycle of Pexa-Vec treatment. (a) IL-6, (b) MIP-1α, (c) MCP-1, (d) IL-8, (e) IL-18, (f) MIP-1β, (g) TNF-α, (h) IL-2, (i) IL-10, (j) IFN-γ, (k) GM-CSF.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

5. Figure 3
Cytokine detection in plasma. Cytokine concentrations were measured in plasma before and after each cycle of Pexa-Vec treatment. (a) IL-6, (b) MIP-1α, (c) MCP-1, (d) IL-8, (e) IL-18, (f) MIP-1β, (g) TNF-α, (h) IL-2, (i) IL-10, (j) IFN-γ, (k) GM-CSF.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

6. Figure 4
Waterfall plot showing maximum percent changes of the sum of longest diameters of target lesions compared to baseline. X-axis: patient numbers.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions